ReviewArchives of gynecology and obstetrics2017
High-grade serous ovarian cancer: the clone wars.
Review in Archives of gynecology and obstetrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.JCO precision oncology · 2025Trial
- Inflammatory milieu and role of epigenetic modifications in high-grade serous ovarian cancer.Clinical epigenetics · 2026Review
- TIMP1 Overexpression in Ovarian Cancer Spheroids: Implications for Prognosis, Resistance, and Metastatic Potential.Cancers · 2025Article
- Uncovering key regulatory pathways and prognostic biomarkers in the tumor microenvironment of high-grade serous ovarian cancer through single-cell RNA sequencing and experimental validation.Frontiers in oncology · 2025Article
- Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.International journal of oncology · 2022Article
- Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time.Biomolecules · 2021Article
- Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications.Diagnostics (Basel, Switzerland) · 2021Review
- NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.Archives of gynecology and obstetrics · 2021Article
- 3D Bioprinted cancer models: Revolutionizing personalized cancer therapy.Translational oncology · 2021Review
- Improving personalized tumor growth predictions using a Bayesian combination of mechanistic modeling and machine learning.Communications medicine · 2021Article
- A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.PloS one · 2021Article
- A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer.Cancers · 2020Article
- Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.Cancer research · 2020Article
- Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer.Insights into imaging · 2020Review
- Epithelial ovarian cancer risk: A review of the current genetic landscape.Clinical genetics · 2020Review
- Dexmedetomidine Regulates Proliferation, Apoptosis, Migration, and Invasion in Ovarian Cancer Cells via MiR-155-HIF-1α Axis.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.Journal of ovarian research · 2019Article
- Effect of dexmedetomidine anesthesia on perioperative levels of TNF-α and IL-6 in patients with ovarian cancer.Oncology letters · 2019Article
- MUS81 Participates in the Progression of Serous Ovarian Cancer Associated With Dysfunctional DNA Repair System.Frontiers in oncology · 2019Article
- Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer.Computational and structural biotechnology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe last 5 years' studies using next-generation sequencing provided evidences that many types of solid tumors present spatial and temporal genetic heterogeneity and are composed of multiple populations of genetically distinct subclones that evolve over time following a pattern of branched evolution. The evolutionary nature of cancer has been proposed as the major contributor to drug resistance and treatment failure. In this review, we present the current state of knowledge about the clonal evolution of high-grade serous ovarian cancer and discuss the challenge that clonal evolution poses for efforts to achieve an optimal cancer control.
methodsA systemic search of peer-reviewed articles published between August 2007 and October 2016 was performed using PUBMED and Google Scholar database. RESULTS AND
conclusionsRecent studies using next-generation sequencing have allowed us to look inside the evolutionary nature of high-grade serous ovarian cancer, which in the light of current evidence can explain the relapsing course of the disease frequently observed in the clinical practice. Since only minimal improvement in the survival of patients treated with standard therapy has been observed in the last decade, novel molecular targeted therapies are of great interest in high-grade serous ovarian cancer. However, both spatial and temporal intratumoral genetic heterogeneity is a major challenge for personalized medicine, and greater knowledge of the molecular rules that drive tumor evolution through space and time is required to achieve a long-term clinical benefit from personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.